文献リスト

1) Heaf JG, Lokkegaard H, Madsen M. Initial survival advantage of peritoneal dialysis relative to haemodialysis. Nephrol Dial Transplant. 2002; 17: 112-7

2) Liem YS, Wong JB, Hunink MG, et al. Comparison of hemodialysis and peritoneal dialysis survival in The Netherlands. Kidney Int. 2007; 71: 153-8

3) Davies SJ, Woodrow G, Donovan K, et al. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol. 2003; 14: 2338-44

4) Finkelstein F, Healy H, Abu-Alfa A, et al. Superiority of icodextrin compared with 4. 25% dextrose for peritoneal ultrafiltration. J Am Soc Nephrol. 2005; 16: 546-54

5) Bajo MA, Selgas R, Castro MA, et al. Icodextrin effluent leads to a greater proliferation than glucose effluent of human mesothelial cells studied ex vivo. Perit Dial Int. 2000; 20: 742-7

6) Babazono T, Nakamoto H, Kasai K, et al. Effects of icodextrin on glycemic and lipid profiles in diabetic patients undergoing peritoneal dialysis. Am J Nephrol. 2007; 27: 409-15

7) Takeguchi F, Nakayama M, Nakao T. Effects of icodextrin on insulin resistance and adipocytokine profiles in patients on peritoneal dialysis. Ther Apher Dial. 2008; 12: 243-9

8) Kuriyama R, Tranaeus A, Ikegami T. Icodextrin reduces mortality and the drop-out rate in Japanese peritoneal dialysis patients. Adv Perit Dial. 2006; 22: 108-10

9) Ota K, Akiba T, Nakao T, et al. Peritoneal ultrafiltration and serum icodextrin concentration during dialysis with 7. 5% icodextrin solution in Japanese patients. Perit Dial Int. 2003; 23: 356-61

10) Moriishi M, Kawanishi H, Tsuchiya S. Impact on peritoneal membrane of use of icodextrin-based dialysis solution in peritoneal dialysis patients. Adv Perit Dial. 2006; 22: 24-8

11) Sitter T, Haslinger B, Mandl S, et al. High glucose increases prostaglandin E2 synthesis in human peritoneal mesothelial cells: role of hyperosmolarity. J Am Soc Nephrol. 1998; 9: 2005-12

12) Tamura M, Osajima A, Nakayamada S, et al. High glucose levels inhibit focal adhesion kinase-mediated wound healing of rat peritoneal mesothelial cells. Kidney Int. 2003; 63: 722-31

13) Matsuo H, Tamura M, Kabashima N, et al. Prednisolone inhibits hyperosmolarity-induced expression of MCP-1 via NF-kappaB in peritoneal mesothelial cells. Kidney Int. 2006; 69: 736-46

14) Zakaria el R, Patel AA, Li N, et al. Vasoactive components of dialysis solution. Perit Dial Int. 2008; 28: 283-95

15) Mujais S, Vonesh E. Profiling of peritoneal ultrafiltration. Kidney Int. 2002; 62: S17-22

16) Canepa A, Verrina E, Perfumo F. Use of new peritoneal dialysis solutions in children. Kidney Int. 2008; 73: S137-44

17) Nakamoto H, Babazono T, Kasai K, et al. Successful use of icodextrin in elderly patients on continuous ambulatory peritoneal dialysis. Adv Perit Dial. 2005; 21: 168-74

18) Davies SJ, Brown EA, Frandsen NE, et al. Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int. 2005; 67: 1609-15

19) Dallas F, Jenkins SB, Wilkie ME. Enhanced ultrafiltration using 7. 5% icodextrin/1. 36% glucose combination dialysate: a pilot study. Perit Dial Int. 2004; 24: 542-6

20) Konings CJ, Kooman JP, Gladziwa U, et al. A decline in residual glomerular filtration during the use of icodextrin may be due to underhydration. Kidney Int. 2005; 67: 1190-1

21) Wolfson M, Piraino B, Hamburger RJ, et al. A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis. 2002; 40: 1055-65

22) Konings CJ, Kooman JP, Schonck M, et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study. Kidney Int. 2003; 63: 1556-63

23) Paniagua R, Orihuela O, Ventura MD, et al. Echocardiographic, electrocardiographic and blood pressure changes induced by icodextrin solution in diabetic patients on peritoneal dialysis. Kidney Int. 2008: 73: S125-30

24) Furuya R, Odamaki M, Kumagai H, et al. Beneficial effects of icodextrin on plasma level of adipocytokines in peritoneal dialysis patients. Nephrol Dial Transplant. 2006; 21: 494-8

25) Gursu EM, Ozdemir A, Yalinbas B, et al. The effect of icodextrin and glucose-containing solutions on insulin resistance in CAPD patients. Clin Nephrol. 2006; 66: 263-8

26) Canbakan M, Sahin GM. Icodextrine and insulin resistance in continuous ambulatory peritoneal dialysis patients. Ren Fail. 2007; 29: 289-93

27) Bredie SJ, Bosch FH, Demacker PN, et al. Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. Perit Dial Int. 2001; 21: 275-81

28) Martikainen T, Teppo AM, Gronhagen-Riska C, et al. Benefit of glucose-free dialysis solutions on glucose and lipid metabolism in peritoneal dialysis patients. Blood Purif. 2005; 23: 303-10

29) Teta D, Maillard M, Halabi G, et al. The leptin/adiponectin ratio: potential implications for peritoneal dialysis. Kidney Int. 2008: 73: S112-8

30) Gotloib L, Wajsbrot V, Shostak A. Mesothelial dysplastic changes and lipid peroxidation induced by 7. 5% icodextrin. Nephron. 2002; 92: 142-55

31) Czupryniak A, Nowicki M, Chwatko G, et al. Peritoneal clearance of homocysteine with icodextrin or standard glucose solution exchange. Nephrology (Carlton). 2005; 10: 571-5

32) Adachi Y, Nakagawa Y, Nishio A. In patients treated with peritoneal dialysis, icodextrin improves erythropoietin-resistant anemia through blockade of asialo receptors on hepatocytes. Adv Perit Dial. 2006; 22: 41-4

33) Ahmad S, Sehmi JS, Ahmad-Zakhi KH, et al. Impact of new dialysis solutions on peritonitis rates. Kidney Int. 2006: 70; S63-6

34) Vychytil A, Remon C, Michel C, et al. Icodextrin does not impact infectious and culture-negative peritonitis rates in peritoneal dialysis patients: a 2-year multicentre, comparative, prospective cohort study. Nephrol Dial Transplant. 2008; 23: 3711-9

35) Krediet R, Mujais S. Use of icodextrin in high transport ultrafiltration failure. Kidney Int Suppl. 2002; (81): S53-61.

36) Martikainen T, Ekstrand A, Honkanen E, et al. Do interleukin-6, hyaluronan, soluble intercellular adhesion molecule-1 and cancer antigen 125 in dialysate predict changes in peritoneal function？ A 1-year follow-up study. Scand J Urol Nephrol. 2005; 39: 410-6

37) De Vriese AS, Tilton RG, Mortier S, et al. Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia. Nephrol Dial Transplant. 2006; 21: 2549-55

38) Aroeira LS, Aguilera A, Sanchez-Tomero JA, et al. Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. J Am Soc Nephrol. 2007; 18: 2004-13

39) Posthuma N, ter Wee PM, Niessen H, et al. Amadori albumin and advanced glycation end-product formation in peritoneal dialysis using icodextrin. Perit Dial Int. 2001; 21: 43-51

40) Conti G, Amore A, Cirina P, et al. Glycated adducts induce mesothelial cell transdifferentiation: role of glucose and icodextrin dialysis solutions. J Nephrol. 2008; 21: 426-37

41) Katsutani M, Ito T, Masaki T, et al. Glucose-based PD solution, but not icodextrin-based PD solution, induces plasminogen activator inhibitor-1 and tissue-type plasminogen activator in human peritoneal mesothelial cells via ERK1/2. Ther Apher Dial. 2007; 11: 94-100

42) Ha H, Cha MK, Choi HN, et al. Effects of peritoneal dialysis solutions on the secretion of growth factors and extracellular matrix proteins by human peritoneal mesothelial cells. Perit Dial Int. 2002; 22: 171-7

43) Mortier S, Faict D, Gericke M, et al. Effects of new peritoneal dialysis solutions on leukocyte recruitment in the rat peritoneal membrane. Nephron Exp Nephrol. 2005; 101: e139-45

44) Kossi J, Gronlund S, Uotila-Nieminen M, et al. The effect of 4% icodextrin solution on adhesiolysis surgery time at the Hartmann's reversal. A pilot, multi-centre, RCT versus lactated Ringer's solution (LRS). Colorectal Dis. 2008; e-pub ahead

45) Cooker LA, Choo CG, Luneburg P, et al. Effect of icodextrin peritoneal dialysis solution on cell proliferation in vitro. Adv Perit Dial. 1999; 15: 17-20

46) Ha H, Yu MR, Choi HN, et al. Effects of conventional and new peritoneal dialysis solutions on human peritoneal mesothelial cell viability and proliferation. Perit Dial Int. 2000; 20 Suppl 5: S10-8

47) Tamura M, Kabashima N, Serino R, et al. Effects of icodextrin on cell adhesion molecules in peritoneal mesothelial cells. J Am Soc Nephrol. 2007; 18: 75A

48) Boulanger E, Wautier MP, Gane P, et al. The triggering of human peritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxydation products. Nephrol Dial Transplant. 2004; 19: 2208-2216

49) Woodrow G, Stables G, Oldroyd B, et al. Comparison of icodextrin and glucose solutions for the daytime dwell in automated peritoneal dialysis. Nephrol Dial Transplant. 1999; 14: 1530-5

50) Konings CJ, Schalkwijk CG, van der Sande FM, et al. Influence of icodextrin on plasma and dialysate levels of N(epsilon)-(carboxymethyl) lysine and N(epsilon)-(carboxyethyl)lysine. Perit Dial Int. 2005; 25: 591-5

51) Martikainen TA, Teppo AM, Gronhagen-Riska C, et al. Glucose-free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane？ Perit Dial Int. 2005; 25: 453-60

52) Moriishi M, Kawanishi H, Watanabe H, et al. Effect of icodextrin-based peritoneal dialysis solution on peritoneal membrane. Adv Perit Dial. 2005; 21: 21-4

53) Parikova A, Zweers MM, Struijk DG, et al. Peritoneal effluent markers of inflammation in patients treated with icodextrin-based and glucose-based dialysis solutions. Adv Perit Dial. 2003; 19: 186-90

54) van Hoeck KJ, Rusthoven E, Vermeylen L, et al. Nutritional effects of increasing dialysis dose by adding an icodextrin daytime dwell to Nocturnal Intermittent Peritoneal Dialysis (NIPD) in children. Nephrol Dial Transplant. 2003; 18: 1383-7

55) Moberly JB, Mujais S, Gehr T, et al. Pharmacokinetics of icodextrin in peritoneal dialysis patients. Kidney Int. 2002: 62: S23-33

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp